Candidate counterparts of sezary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: An ultrastructural study with the immunogold method and monoclonal antibodies

Matutes, E.; Robinson, D; O’Brien, Maureen M.; Haynes, Barton F.; Zola, Heddy; Catovsky, Daniel

doi:10.1016/0145-2126(83)90073-5

Cited by 49 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The morphologic detection of Sezary cells in the peripheral blood is not specific for CTCL, as Sezary cells may be found in peripheral blood from normal donors and in benign conditions [124][125][126]. The histologic findings in the skin often resemble those observed in MF, with less prominent epidermotropism, while lymph node involvement is characterized by complete effacement of the nodal architecture by infiltrating Sezary cells [127].…”

mentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

mentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Mycosis fungoides represents the vast majority of all CTCLs. In this disease, the transformed cell is a clonal CD4 ϩ CD7 Ϫ CD26 Ϫ memory T cell with a bizarrely shaped nucleus (1)(2)(3)(4). In early disease stage, these CTCL cells show a high degree of tropism for skin epithelium, whereas in later disease stages dermal infiltration predominates.…”

Section: Utaneous T Cell Lymphoma (Ctcl)mentioning

confidence: 99%

“…Remaining erythrocytes were lysed osmotically in a buffer containing 0.15 M NH 4 Cl, 1 mM KHCO 3 , and 0.1 mM EDTA (all from Sigma-Aldrich). CD8 ϩ T cells were enriched by anti-CD4, anti-CD11b, anti-CD16, anti-CD19, anti-CD34, and anti-CD56 mAb (all by Beckman Coulter)-based immunomagnetic depletion (MACS; Miltenyi Biotec).…”

Section: Cellsmentioning

confidence: 99%

Down-Modulation of CXCR3 Surface Expression and Function in CD8+ T Cells from Cutaneous T Cell Lymphoma Patients

Winter

Moser

Kriehuber

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

Viruses can escape destruction by the immune system by exploitation of the chemokine-chemokine receptor system. It is less established whether human cancers can adopt similar strategies to evade immunologic control. In this study, we show that advanced cutaneous T cell lymphoma (CTCL) is associated with selective and efficient inactivation of CXCR3-dependent T cell migration. Our studies demonstrate that this alteration is at least in part due to CXCR3 down-regulation in vivo by elevated serum levels of CXCR3 ligands. The T cell population most affected by this down-regulatory mechanism are CD8+ cytotoxic effector T cells. In CTCL patients, cytotoxic effector T cells have strongly reduced surface CXCR3 expression, accumulate in peripheral blood, but are virtually absent from CTCL tumor lesions, indicating an inability to extravasate into lymphoma tissue. CTCL-associated inactivation of effector cell recruitment may be a paradigmatic example of a new type of immune escape mechanisms shielding the neoplasm from a tumoricidal attack.

show abstract

“…Peripheral blood and bone marrow samples from healthy donors and 16 leukaemic patients: 9 acute leukaemias and 7 blast crisis from CGL [3] and MF [4] …”

Section: B Materials and Methodsmentioning

confidence: 99%

“…A combination of immunological and electron microscope (EM) techniques can now be carried out by using electron-dense tracers such as colloidal gold particles to visualise the reaction with a monoclonal antibody (MoAb )-immuno gold method (IGM) [I]. Application of this technique has allowed the characterisation of distinct T lymphocyte subpopulations in normal blood [2,3]. In this study we analyse by this method the expression of various lineage-specific membrane antigens in normal haemopoietic precursor cells and in blast cells from patients with acute leukaemia and blast crisis from chronic granulocytic leukaemia (CGL) and myelofibrosis (MF) to see if a more precise characterisation of the immature cells can be made.…”

Section: A Introductionmentioning

confidence: 99%

Ultrastructural Analysis of Normal and Leukaemic Cells by the Immunogold Method and Monoclonal Antibodies

Matutes¹,

Catovsky²

1985

Modern Trends in Human Leukemia VI New Results in Clinical and Biological Research Including Pediatric Oncology

View full text Add to dashboard Cite

Candidate counterparts of sezary cells and adult T-cell lymphoma-leukaemia cells in normal peripheral blood: An ultrastructural study with the immunogold method and monoclonal antibodies

Cited by 49 publications

References 21 publications

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Down-Modulation of CXCR3 Surface Expression and Function in CD8+ T Cells from Cutaneous T Cell Lymphoma Patients

Ultrastructural Analysis of Normal and Leukaemic Cells by the Immunogold Method and Monoclonal Antibodies

Contact Info

Product

Resources

About